These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 6336551)

  • 41. Elimination of hypercapnia may postpone the clinical presentation of malignant hyperthermia: a case report.
    Chia YY; Liu YC; Lee MC; Lo Y; Liu K
    Zhonghua Yi Xue Za Zhi (Taipei); 1998 Apr; 61(4):230-4. PubMed ID: 9614782
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Postexercise muscle cramping associated with positive malignant hyperthermia contracture testing.
    Ogletree JW; Antognini JF; Gronert GA
    Am J Sports Med; 1996; 24(1):49-51. PubMed ID: 8638753
    [No Abstract]   [Full Text] [Related]  

  • 43. [Malignant hyperthermia: new developments in diagnosis and clinical management].
    Dépret T; Krivosic-Horber R
    Ann Fr Anesth Reanim; 2001 Dec; 20(10):838-52. PubMed ID: 11803844
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rhabdomyolysis after infection and taking a cold medicine in a patient who was susceptible to malignant hyperthermia.
    Kasamatsu Y; Osada M; Ashida K; Azukari K; Yoshioka K; Ohsawa A
    Intern Med; 1998 Feb; 37(2):169-73. PubMed ID: 9550599
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intraoperative hyperthermia in a paediatric patient with cystinosis.
    Purday JP; Montgomery CJ; Blackstock D
    Paediatr Anaesth; 1995; 5(6):389-92. PubMed ID: 8597974
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Management of suspected malignant hyperpyrexia in an infant.
    Faust DK; Gergis SD; Sokoll MD
    Anesth Analg; 1979; 58(1):33-5. PubMed ID: 571220
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Tests of contracture and sensitivity to malignant hyperthermia in 27 patients].
    Krivosic-Horber R; Adnet P; Krivosic I; Theunynck D; Guévart E; Adamantidis M
    Ann Fr Anesth Reanim; 1988; 7(2):132-8. PubMed ID: 3364812
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Contracture test and histologic and histochemical analyses of muscle biopsy specimens from horses with exertional rhabdomyolysis.
    Hildebrand SV; Arpin D; Cardinet G
    J Am Vet Med Assoc; 1990 Apr; 196(7):1077-83. PubMed ID: 2329077
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Contractile elements in muscular fascial tissue - implications for in-vitro contracture testing for malignant hyperthermia.
    Hoppe K; Schleip R; Lehmann-Horn F; Jäger H; Klingler W
    Anaesthesia; 2014 Sep; 69(9):1002-8. PubMed ID: 24909539
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Is resting membrane potential a possible indicator of viability of muscle bundles used in the in vitro caffeine contracture test?
    Adnet PJ; Krivosic-Horber RM; Adamantidis MM; Haudecoeur G; Reyford HG; Dupuis BA
    Anesth Analg; 1992 Jan; 74(1):105-11. PubMed ID: 1734769
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Malignant hyperthermia in the oral and maxillofacial surgery patient: an update.
    Patil PM
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2011 Sep; 112(3):e1-7. PubMed ID: 21827956
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A blinded comparison of noninvasive, in vivo phosphorus nuclear magnetic resonance spectroscopy and the in vitro halothane/caffeine contracture test in the evaluation of malignant hyperthermia susceptibility.
    Olgin J; Rosenberg H; Allen G; Seestedt R; Chance B
    Anesth Analg; 1991 Jan; 72(1):36-47. PubMed ID: 1984374
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Serum creatine kinase level as a screening test for susceptibility to malignant hyperthermia.
    Paasuke RT; Brownell AK
    JAMA; 1986 Feb; 255(6):769-71. PubMed ID: 3944979
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Influence of propranolol on the in vitro response to caffeine and halothane in malignant hyperthermia-susceptible muscle.
    Ording H
    Acta Anaesthesiol Scand; 1989 Jul; 33(5):405-8. PubMed ID: 2800978
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Malignant hyperthermia in the otology patient: the UCLA experience.
    Wackym PA; Blackwell KE
    Am J Otol; 1994 May; 15(3):371-5. PubMed ID: 8579142
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety of general anesthesia in patients previously tested negative for malignant hyperthermia susceptibility.
    Allen GC; Rosenberg H; Fletcher JE
    Anesthesiology; 1990 Apr; 72(4):619-22. PubMed ID: 2321777
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Malignant hyperthermia-associated diseases: state of the art uncertainty.
    Litman RS; Rosenberg H
    Anesth Analg; 2009 Oct; 109(4):1004-5. PubMed ID: 19762722
    [No Abstract]   [Full Text] [Related]  

  • 58. Porcine malignant hyperthermia--failure of dantrolene dose response to diagnose susceptibility (halothane effect).
    Flewellen EH; Nelson TE; Bee DE
    Can Anaesth Soc J; 1980 Jan; 27(1):16-21. PubMed ID: 7353186
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rationale for dantrolene vs. procainamide for treatment of malignant hyperthermia.
    Nelson TE; Flewellen EH
    Anesthesiology; 1979 Feb; 50(2):118-22. PubMed ID: 434484
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Malignant hyperthermia (MH) diagnostics: a comparison between the halothane-caffeine- and the ryanodine-contracture-test results in MH susceptible, normal and control muscle.
    Hartung E; Koob M; Anetseder M; Schoemig P; Krauspe R; Hogrefe G; Engelhardt W
    Acta Anaesthesiol Scand; 1996 Apr; 40(4):437-44. PubMed ID: 8738688
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.